Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 58 · MACD above its signal
None of the 29 investors followed here reported a position in 1952.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1952.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 3.43 per share. | 8K | $27.44K |
| Sep 9, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 3.66 per share. | 20K | $73.22K |
| Jun 29, 2026 | Luo (Yongqing)Chief Executive Officer | — | 110.9K | — |
| Jun 29, 2026 | Woo (Ian Ying)President | — | 52.9K | — |
| Jun 3, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 3.68 per share. | 20K | $73.52K |
| May 18, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 3.90 per share. | 20K | $78.03K |
| May 12, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 3.98 per share. | 9K | $35.81K |
| May 7, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 4.17 per share. | 9.5K | $39.63K |
| Apr 28, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 4.50 per share. | 10K | $44.99K |
| Apr 26, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 4.51 per share. | 5.5K | $24.83K |
| Mar 26, 2026 | Wu (Yifang)Chairman of the Board | Acquisition at price 4.55 per share. | 11.5K | $52.33K |
| Dec 30, 2025 | Luo (Yongqing)Chief Executive Officer | — | 120K | — |
| Dec 30, 2025 | Woo (Ian Ying)President | — | 100K | — |
| Dec 30, 2025 | Wu (Yifang)Chairman of the Board | Acquisition at price 4.88 per share. | 30K | $146.41K |
| Dec 11, 2025 | Luo (Yongqing)Chief Executive Officer | Acquisition at price 5.82 per share. | 132.5K | $771.80K |
| Dec 11, 2025 | Woo (Ian Ying)President | Acquisition at price 5.85 per share. | 98.2K | $574.41K |
| Dec 11, 2025 | Wu (Yifang)Chairman of the Board | Acquisition at price 5.78 per share. | 277K | $1.60M |
| Jun 29, 2025 | Luo (Yongqing)Chief Executive Officer | — | 240K | — |
| Jun 29, 2025 | Woo (Ian Ying)President | — | 28.1K | — |
| Mar 31, 2025 | Luo (Yongqing)Chief Executive Officer | — | 59.4K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.1 | -2.9 | -0.8 | -7.9 | -12.7 | -18.7 | 3.3 | 28.4 | -7.2 | 5.8 | −14.0% | ||
| 2025 | -15.9 | 15.6 | 14.4 | -8.0 | -10.4 | 40.9 | 2.7 | -0.5 | -11.4 | -13.0 | -3.8 | -21.3 | −23.0% |
| 2024 | -25.0 | 54.0 | -2.7 | 4.0 | -9.8 | -11.2 | -0.2 | 5.9 | 31.2 | 16.0 | 8.9 | 40.4 | +130.4% |
| 2023 | 43.8 | -32.0 | -9.2 | -7.9 | -23.5 | 118.7 | -8.6 | -16.8 | 38.1 | 11.2 | -26.4 | 2.2 | +20.3% |
| 2022 | -23.1 | -6.6 | 8.1 | -29.1 | 19.8 | 2.0 | -27.6 | -26.5 | -37.3 | -17.6 | 85.4 | 51.7 | −48.0% |
| 2021 | 24.4 | -4.3 | -8.6 | -6.6 | 9.1 | 3.1 | -23.8 | -18.5 | 2.5 | -8.6 | -21.2 | -5.6 | −50.6% |
| 2020 | 8.8 | 7.3 | +16.7% |
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. The company was incorporated in 2017 and is based in Shanghai, China.
Buy / hold / sell counts
No recent headlines.